华仁药业：子公司再获原料药批件 原料+制剂一体化助力药品全生命周期管理

Core Viewpoint - Huarun Pharmaceutical has made significant progress in its integrated development of "raw materials + formulations" by obtaining a new approval for the active pharmaceutical ingredient Pirfenidone, which is used for idiopathic pulmonary fibrosis [1] Group 1: Company Developments - Huarun Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received the approval notice for the listing application of Pirfenidone raw material, marking a strategic achievement in the company's integrated development [1] - Since acquiring Anhui Hengxing Pharmaceutical in 2021, Huarun has expanded its business from large-volume infusions and nephrology to respiratory and controlled substances, laying a historical foundation for its integrated development [1] - Anhui Hengxing has successfully obtained 11 raw material and 8 formulation approvals since the acquisition [1] Group 2: Industry Context - The pharmaceutical industry is facing increasing competition and profit compression due to healthcare cost control measures, centralized procurement, and price linkage policies [1] - Companies with scale, cost, quality advantages, and comprehensive lifecycle management capabilities are better positioned to survive and thrive in the competitive landscape [1] Group 3: Broader Industry Chain Integration - Huarun Pharmaceutical is deepening its full industry chain layout, including raw materials, formulations, medical devices, and health products, to enhance overall quality and cost control [2] - The company’s subsidiary, Qingdao Huarun Medical Supplies, has obtained 13 Class II medical device registrations and 3 Class I medical device filings in 2024, with a total of 35 Class II and 37 Class I medical devices approved to date [2] - Huarun's Qingdao factory produces packaging materials that support large-volume formulations, leveraging the integrated factory advantages to create a professional green packaging innovation center [2] Group 4: Health and Wellness Sector - Huarun's subsidiary, Hubei Huarun Tongji Pharmaceutical, is a joint platform with Tongji Hospital, focusing on the health and wellness sector, and has recently obtained a cosmetics production license to enhance its market competitiveness [3] - The company has been recognized as one of the "Top 100 Chinese Pharmaceutical Industries" for five consecutive years, with its ranking rising to 71st [3] - Huarun aims to leverage its lifecycle management logic to navigate the new industry development cycle in the centralized procurement era [3]